51838 Federal Register / Vol. 71, No. 169 / Thursday, August 31, 2006 / Notices 

responses in patients with autoimmune 

diseases; (3) Development of vaccines 

candidates for cancer and infectious 

diseases; (4) Organ transplant 

diagnostics and immunotherapeutics. 

Inventors: William Biddison, Richard 

Turner, Susan Gagnon (NINDS). 

Relevant Publications: 

1. TK Baxter, SJ Gagnon, RL DavisHarrison, JC Beck, AK Binz, RV Turner, 

WE Biddison. Strategic mutations in the 

class I major histocompatibility complex 

HLA–A2 independently affect both 

peptide binding and T cell receptor 

recognition. J. Biol. Chem. 2004 Jul 9; 

279(28):29175–29184. 

2. BM Baker, RV Turner, SJ Gagnon, 

DC Wiley, WE Biddison. Identification 

of a crucial energetic footprint on the 

alpha1 helix of human 

histocompatibility leukocyte antigen 

(HLA)–A2 that provides functional 

interactions for recognition by tax 

peptide/HLA–A2-specific T cell 

receptors. J. Exp. Med. 2001 Mar 5; 

193(5):551–562. 

Patent Status: HHS Reference Nos. E–

251–2006/0 and E–251–2006/1—

Biological Materials. 

Licensing Status: Available for 

licensing through Biological Materials 

License Agreements. 

Licensing Contact: Susan Ano, Ph.D.; 

301/435–5515; anos@mail.nih.gov. 

Neutralizing Monoclonal Antibodies to 

Botulinum Neurotoxin A 

Description of Technology: Available 

for licensing from the NIH are two 

chimpanzee-derived monoclonal 

antibodies (mAbs) against botulinum 

neurotoxin type A (BoNT/A). These 

mAbs can be developed for prevention, 

therapy, or diagnosis of BoNT/A. Use of 

this technology represents a significant 

improvement over the existing therapy 

of supportive care and treatment with 

equine antitoxin polyclonal antibodies. 

Potential Applications of Technology: 

(1) Emergency prophylaxis against 

BoNT/A outbreak (natural or 

biodefense-related); (2) Therapeutic 

against BoNT/A; (3) Rapid Diagnosis of 

BoNT/A; (4) Therapeutic against 

overdosage of BoNT/A as used in 

clinical treatments. 

Advantages of Existing Therapies: (1) 

No anticipated side effects compared to 

currently utilized equine antitoxin 

polyclonal antibodies; (2) Monoclonal 

instead of polyclonal. 

Inventors: Robert H. Purcell et al. 

(NIAID). 

Patent Status: HHS Reference No. E–

180–2006/0—Research Tool. 

Licensing Status: Available for nonexclusive licensing. 

Licensing Contact: Susan Ano, Ph.D.; 

301/435–5515; anos@mail.nih.gov. 

Dated: August 25, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 06–7331 Filed 8–30–06; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Initial Review Group, Subcommittee 

F—Manpower & Training, NCI F—Initial 

Review of K01 and T32 Applications. 

Date: September 26–27, 2006. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Georgetown, 2101 

Wisconsin Avenue, NW., Washington, DC 

20007. 

Contact Person: Lynn M. Amende, PhD, 

Scientific Review Administrator, Resources 

and Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd., Room 8105, 

Bethesda MD 20892, 301–451–4759, 

amendel@mail.nih.go. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: August 25, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–7336 Filed 8–30–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Deafness and 

Other Communication Disorders; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel, R03 

Chemosense Scientific Review Panel. 

Date: October 5, 2006. 

Time: 11 a.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6120 

Executive Blvd., Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Sheo Singh, PhD, 

Scientific Review Administrator, Scientific 

Review Branch, Division of Extramural 

Activities, Executive Plaza South, Room 

400C, 6120 Executive Blvd., Bethesda, MD 

20892; 301–496–8683; singhs@nidcd.nih.gov. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel, R03 Voice 

and Language Scientific Review Meeting. 

Date: October 5, 2006. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6120 

Executive Blvd., Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Shiguang Yang, PhD, 

DVM, Scientific Review Administrator, 

Division of Extramural Activities, NIDCD, 

NIH, 6120 Executive Blvd., Bethesda, MD 

20892; 301–496–8683. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel, R03 

Hearing and Balance Scientific Review 

Meeting. 

Date: October 6, 2006. 

Time: 11 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6120 

Executive Blvd., Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Shiguang Yang, PhD, 

DVM, Scientific Review Administrator, 


erjones on PROD1PC72 with NOTICES
Federal Register / Vol. 71, No. 169 / Thursday, August 31, 2006 / Notices 51839 

Division of Extramural Activities, NIDCD, 

NIH, 6120 Executive Blvd., Bethesda, MD 

20892; 301–496–8683. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel, NIDCD 

Research Core Center P30. 

Date: October 13, 2006. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Milcho Mincheff, MD, 

PhD, Scientific Review Administrator, 

Division of Extramural Activities, NIDCD/ 

NIH, EPS, Room 400C, 6120 Executive Blvd., 

MSC 7180, Bethesda, MD 20892; 301–496–

8693; mincheffm@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.173, Biological Research 

Related to Deafness and Communicative 

Disorders, National Institutes of Health, HHS) 

Dated: August 24, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–7332 Filed 8–30–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Initial Review Group, Neuroscience of 

Aging Review Committee. 

Date: October 2–3, 2006. 

Time: 7 p.m. to 11:30 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Louise L. Hsu, PhD, Health 

Scientist Administrator, Scientific Review 

Office, National Institute on Aging, Gateway 

Building, 7201 Wisconsin Avenue/Suite 

2C212, Bethesda, MD 20892, 301–496–7705, 

hsul@exmur.nia.nih.gov. 

Name of Committee: National Institute on 

Aging Initial Review Group, Biological Aging 

Review Committee. 

Date: October 3–4, 2006. 

Time: 6 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Marriott Bethesda Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Bita Nakhai, Scientific 

Review Administrator, Scientific Review 

Office, National Institute on Aging, Gateway 

Building, 2C212 7201 Wisconsin Avenue, 

Bethesda, MD 20814, 301–402–7701, 

nakhaib@nia.nih.gov. 

Name of Committee: National Institute on 

Aging Initial Review Group, Behavior and 

Social Science of Aging Review Committee. 

Date: October 5–6, 2006. 

Time: 3 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Jon E. Rolf, PhD, Scientific 

Review Administrator, Scientific Review 

Office, National Institute on Aging, National 

Institutes of Health, 7201 Wisconsin Avenue/ 

Room 2C212, Bethesda, MD 20814, 301–402–

7703, rolfj@nia.nih.gov. 

Name of Committee: National Institute on 

Aging Initial Review Group, Clinical Aging 

Review Committee. 

Date: October 5–6, 2006. 

Time: 6:30 p.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Residence Inn Marriott, 7335 

Wisconsin Ave., Bethesda, MD 20814. 

Contact Person: Alicja L. Markowska, PhD, 

DSC, National Institute on Aging, National 

Institutes of Health, Gateway Building, 

2C212, 7201 Wisconsin Avenue, Bethesda, 

MD 20892, 301–496–9666, 

markowsa@nia.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: August 25, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–7334 Filed 8–30–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel, AD and 

Cognition. 

Date: September 14, 2006. 

Time: 2 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Gateway Building, 7201 Wisconsin Avenue, 

2C212, Bethesda, MD 20892, (Telephone 

Conference Call). 

Contact Person: Alicja L. Markowska, PhD, 

DSC, Scientific Review Office, National 

Institute on Aging, National Institutes of 

Health, 7201 Wisconsin Avenue, Suite 

2C212, Bethesda, MD 20892. 301–496–9666. 

markowsa@nia.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: August 25, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–7335 Filed 8–30–06; 8:45am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 


erjones on PROD1PC72 with NOTICES